| Customization: | Available |
|---|---|
| Transport Package: | Carton |
| Specification: | Neutral protease |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name | Desloratadine Tablet |
| Main Ingredients | Loratadine |
| Adaptation disease | To relieve chronic idiopathic urticaria and allergic rhinitis related symptoms |
| Dosage form | Troche |
| Character | This product is thin film, white or white after removing the coating |
| Specification | 5mg |
| Usage and dosage | Oral for adults and adolescents 12 years or older: oral, once daily, 1 tablet each time. Taking food does not affect the effect of medication. For patients with intermittent allergic rhinitis (symptoms occurring less than 4 days per week or lasting less than 4 weeks), the patient's history should be evaluated before treatment is scheduled, and treatment should be discontinued when the patient's recurrent symptoms have resolved and recovered. For patients with persistent allergic rhinitis (symptoms occurring 4 or more days per week and lasting longer than 4 weeks), continuous treatment during the acute episode is recommended. |
| Storage | The dry place at 2-25ºC is shielded and sealed |
| Origin | China |
| validity | 24 months |
| Tatoo | This product active ingredient or excipient and loratadine allergy is prohibited |
| Notice | 1. Unknown effects of loratadine on the ability to drive and operate machinery. However, it should be noted that a very small percentage of patients experience sleepiness, which can affect their ability to drive or use machinery. Use with caution in patients with severe renal insufficiency. 2. Desloratadine should be used with caution in patients with a history of epilepsy or family history. Young children, in particular, may be more prone to seizures during desloratadine treatment. During treatment, health care providers may consider discontinuing loratadine if the patient has a seizure. 3. The safety of desloratadine during pregnancy has not been determined due to the absence of clinical data on the use of desloratadine in pregnant women. Desloratadine should not be used during pregnancy unless the potential benefits outweigh the possible risks. Desloratadine can be excreted through milk and is therefore not recommended for lactating women. Desloratadine at 34 times the clinically recommended dose in humans had no effect on overall fertility in rats, and no teratogenic or mutagenic effects of desloratadine were found in animal studies. 4. The efficacy and safety of desloratadine in children under 12 years of age have not been established. |
| Adverse events: in a series of clinical trials for allergic rhinitis and chronic idiopathic urticaria, the incidence of adverse events was 3% higher in the treatment group than in the placebo group when desloratadine was administered at the recommended dose of 5mg per day. The most common adverse events over placebo were tiredness (1.2%), dry mouth (0.8%), and headache (0.6%). In a clinical trial of 578 adolescents ages 12 to 17, the most common adverse event was headache; It occurred in 5.9% of patients treated with desloratadine and 6.9% of patients treated with placebo. The very rare adverse reactions reported after marketing are as follows: hallucinations, dizziness, drowsiness, insomnia, hyperactivity, seizures, tachycardia, palpitations, abdominal pain, nausea, vomiting, dyspepsia, diarrhea, elevated liver enzymes, elevated bilirubin, hepatitis, increased appetite, myalgia, allergic reactions (e.g. Allergies, angioedema, dyspnea, pruritus, rash and urticaria). |
){kind=link}